文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1 3'PPT区变异性及其与整合酶抑制剂耐药的关系

Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究分析了Los Alamos公共数据库中30706例未治疗患者(涵盖6种亚型)及107例INSTI治疗失败患者的3'PPT区序列。结果显示,无论整合酶基因是否存在耐药突变,治疗失败患者的3'PPT序列与未治疗患者一样高度保守。研究认为3'PPT区突变导致INSTI高水平耐药是罕见事件,需特定体内环境和足够长的暴露时间才能被选择。

要点

  • 3'PPT区序列在未治疗和INSTI治疗失败患者中均高度保守。
  • 3'PPT区突变致INSTI高水平耐药是罕见事件,需特定体内环境和足够暴露时间。
  • 需更大规模INSTI治疗失败患者研究明确3'PPT区在体内的作用。

核心结论

  • 3'PPT区突变导致INSTI高水平耐药是罕见事件。
  • 3'PPT区序列在INSTI治疗失败患者中与未治疗患者一样高度保守。

研究设计与样本

  • 分析Los Alamos公共数据库30706例未治疗患者(6种亚型)的3'PPT区序列。
  • 平行分析107例INSTI治疗失败患者的3'PPT区序列。

主要发现

  • 无论整合酶基因是否存在耐药突变,INSTI治疗失败患者的3'PPT序列均高度保守。
  • 未治疗患者的3'PPT序列同样高度保守。

临床怎么用

  • INSTI治疗失败时,3'PPT区突变作为耐药原因的可能性低,但仍需关注。
  • 常规耐药检测主要关注整合酶基因突变,3'PPT区可作为研究性补充。

局限性

  • 3'PPT区在INSTI耐药中的体内作用需更大规模治疗失败患者研究确定。
  • 3'PPT区突变选择需特定体内环境和足够暴露时间,而临床病毒学失败后快速换药通常缩短暴露时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase strand-transfer inhibitors (INSTIs) are efficient at impairing retroviral integration, which is a critical step in HIV-1 replication. To date, resistance to these compounds has been explained by mutations in the viral protein integrase, which catalyses the integration step. Recently, it has been shown that selected mutations in the 3' polypurine tract (3'PPT), a sequence involved in the reverse transcription mechanism, result in high-level resistance to these compounds. This observation was reinforced by the description of a patient who failed INSTI treatment by selecting mutations in the 3'PPT sequence. METHODS: Sequences of the 3'PPT region were analysed in 30706 treatment-naive patients from the public Los Alamos database belonging to six different subtypes and, in parallel, in 107 patients failing INSTI treatment. RESULTS: The analysis showed that the sequences of patients failing INSTI treatment, in the same way as those of treatment-naive patients, are very well conserved regardless of the presence or absence of resistance mutations in the integrase gene. CONCLUSIONS: This study confirms that the selection of a mutation in the 3'PPT region conferring high-level resistance to INSTIs is a rare event. It would require a particular in vivo context and especially a long enough time to be selected, this exposure time being generally reduced by the rapid change of treatment in the case of virological failure. Larger-scale studies in patients with INSTI treatment failure are needed to determine whether the 3'PPT region can play an important role in vivo in INSTI resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Malet I, Delelis O, Nguyen T, et al. Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance. J Antimicrob Chemother. 2019. PMID: 31730161. doi:10.1093/jac/dkz377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。